Study of LG00313112 for advanced tumors with TP53 Y220C mutation
Part of Cancer, Digestive system, Hormones & metabolism, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This trial tests a new drug called LG00313112 in people with advanced solid tumors that have a specific genetic change called TP53 Y220C. The drug is designed to target tumors with this mutation, and the study aims to see if it can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- Your cancer is advanced (cannot be removed with surgery or has spread) and has a TP53 Y220C mutation.
- Your cancer has gotten worse during or after your last treatment, or you cannot tolerate standard treatments.
- You have measurable disease (tumors that can be seen on scans).
- You are physically able to care for yourself (ECOG performance status 0-1).
- Your organs are functioning well enough (kidney, liver, heart, etc.).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of therapy (NT-175) for people with certain advanced cancers that have a specific genetic change. It might help if your tumor has the TP53 R175H mutation and you have the HLA-A*02:01 immune marker.
This trial tests a personalized cell therapy that uses your own immune cells, modified to target a specific genetic mutation found in some tumors. It aims to see if this treatment can shrink tumors or slow their growth in people with advanced cancer.
This trial tests an experimental drug for people with advanced solid tumors or lymphoma that has not responded to standard treatments and has a specific genetic change (loss of MTAP or CDKN2A genes). The drug is taken by mouth and may work by targeting cancer cells with this change.
This trial tests a new drug (rezatapopt) for people with advanced cancers that have a specific change in the TP53 gene, called Y220C. The drug is designed to target this change and may slow or stop cancer growth. Some participants may also receive an immunotherapy drug called pembrolizumab (Keytruda).
This trial tests a new study drug, GV20-0251, for people with advanced solid tumors that no longer respond to standard therapies. It aims to see if the drug can shrink tumors or slow their growth.
This trial tests a new drug called CLSP-1025 for people with advanced solid tumors that have a specific change in the p53 gene (R175H). The drug targets this change to help fight the cancer.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.